Publications by authors named "K Kalra"
This paper reviews the distinct clinical, pathophysiological, and therapeutic challenges faced by older women undergoing percutaneous coronary intervention (PCI). Older women present with a greater comorbidity burden, smaller coronary vessels, and post-menopausal hormonal changes, which increase procedural complexity and adverse cardiovascular outcomes. Despite these challenges, older women are less likely to receive evidence-based therapies, resulting in higher risks of major adverse cardiovascular events (MACE) and bleeding.
View Article and Find Full Text PDFArticle Synopsis
- * Transcatheter aortic valve replacement (TAVR) has shown similar outcomes in selected patients with bicuspid and tricuspid pathology, which raises questions about its effectiveness in younger patients with longer life expectancies.
- * Future research needs well-designed randomized controlled trials to determine the best treatment for bicuspid aortic stenosis, and there's uncertainty about how to approach patient enrollment in these studies.
Background: Older adults with non-ST-segment-elevation acute coronary syndrome are less likely to undergo an invasive strategy compared with younger patients. Randomized controlled trials traditionally exclude older adults because of their high burden of geriatric conditions.
Methods And Results: We searched for randomized controlled trials comparing invasive versus medical management or a selective invasive (conservative) strategy for older patients (age≥75 years) with non-ST-segment-elevation acute coronary syndrome.
Article Synopsis
- Colchicine has shown some effectiveness in reducing adverse cardiovascular events (ACE) and myocardial infarctions (MI) in patients with coronary artery disease, but its impact on stroke risk is unclear, with conflicting results.
- A systematic review of 16 randomized controlled trials involving nearly 25,000 patients revealed that while colchicine significantly lowered ACE and MI risks by 33% and 21% respectively, it did not significantly affect stroke incidence or mortality rates.
- Overall, colchicine might be beneficial for certain cardiovascular outcomes, but it does not appear to reduce the risk of stroke or affect mortality rates in the studied population.